Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/8056
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSalah-Uddin, Hasib-
dc.contributor.authorScarr, Elizabeth-
dc.contributor.authorPavey, Geoffrey-
dc.contributor.authorHarris, Kriss-
dc.contributor.authorHagan, Jim J.-
dc.contributor.authorDean, Brian-
dc.contributor.authorChalliss, R. A. John-
dc.contributor.authorWatson, Jeannette M.-
dc.date.accessioned2010-06-16T14:09:48Z-
dc.date.available2010-06-16T14:09:48Z-
dc.date.issued2009-08-
dc.identifier.citationNeuropsychopharmacology, 2009, 34 (9), pp. 2156–2166.en_GB
dc.identifier.issn0893-133X-
dc.identifier.urihttp://www.nature.com/npp/journal/v34/n9/full/npp200941a.htmlen_GB
dc.identifier.urihttp://hdl.handle.net/2381/8056-
dc.description.abstractAlterations in muscarinic acetylcholine receptor (CHRM) populations have been implicated in the pathology of schizophrenia. Here we have assessed whether the receptor function of the M1 subtype (CHRM1) is altered in a sub-population of patients with schizophrenia, defined by marked (60–80%) reductions in cortical [3H]-pirenzepine (PZP) binding, and termed ‘muscarinic receptor-deficit schizophrenia’ (MRDS). Using a [35S]-GTPγS-Gαq/11 immunocapture method we have assessed whether CHRM1 signalling in human cortex (Brodmann area 9 (BA9)) is altered in post mortem tissue from a MRDS group compared with a subgroup of patients with schizophrenia displaying normal PZP binding, and controls with no known history of psychiatric or neurological disorders. The CHRM agonist (oxotremorine-M) and a CHRM1-selective agonist (AC-42) increased Gαq/11-[35S]-GTPγS binding, with AC-42 producing responses that were ~50% of those maximally evoked by the full agonist, oxotremorine-M, in control and subgroups of patients with schizophrenia. However, the potency of oxotremorine-M to stimulate Gαq/11-[35S]-GTPγS binding was significantly decreased in the MRDS group (pEC50 (M)=5.69±0.16) compared with the control group (6.17±0.10) and the non-MRDS group (6.05±0.07). The levels of Gαq/11 protein present in BA9 did not vary with diagnosis. Maximal oxotremorine-M-stimulated Gαq/11-[35S]-GTPγS binding in BA9 membranes was significantly increased in the MRDS group compared with the control group. Similar, though non-statistically significant, trends were observed for AC-42. These data provide evidence that both orthosterically and allosterically acting CHRM agonists can stimulate a receptor-driven functional response ([35S]-GTPγS binding to Gαq/11) in membranes prepared from post mortem human dorsolateral prefrontal cortex of patients with schizophrenia and controls . Furthermore, in a subgroup of patients with schizophrenia displaying markedly decreased PZP binding (MRDS) we have shown that although agonist potency may decrease, the efficacy of CHRM1-Gαq/11 coupling increases, suggesting an adaptative change in receptor-G protein coupling efficiency in this endophenotype of patients with schizophrenia.en_GB
dc.language.isoenen_GB
dc.publisherNature Publishing Groupen_GB
dc.rightsThis is the author's final draft of the paper published as Neuropsychopharmacology, 2009, 34 (9), pp. 2156–2166. The final version is available from http://www.nature.com/npp/journal/v34/n9/abs/npp200941a.html. Doi: 10.1038/npp.2009.41-
dc.titleAltered M1 Muscarinic Acetylcholine Receptor (CHRM1)-Gαq/11 Coupling in a Schizophrenia Endophenotypeen_GB
dc.typeArticleen_GB
dc.identifier.doi10.1038/npp.2009.41-
Appears in Collections:Published Articles, Dept. of Cell Physiology and Pharmacology

Files in This Item:
File Description SizeFormat 
SalahUddin_etal_Neuropsychopharmacol(2009)34_2156[ACCEPTEDVERSION].pdf677.02 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.